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Imatinib is a selective tyrosine kinase inhibitor that can block
activity of the platelet-derived growth factor receptor
(PDGFR) and that has immunomodulatory effects on various
cell types. Here we measured the protective effects of
imatinib in Wistar-Kyoto rats with nephrotoxic serum
nephritis, a kidney disease model where CD8þ T cells and
macrophages play pathogenetic roles. Groups of animals
were given imatinib from one day before up to 13 days
following induction of nephritis and from day 7 to 20
following disease induction. Compared to control rats, at
each time point imatinib treatment caused significantly less
proteinuria, lowered serum blood urea nitrogen and
creatinine, and decreased the number of glomeruli with
necrosis, crescents, and fibrin deposits. Imatinib-treated rats
had a significant reduction in glomerular macrophage
accumulation and reduced renal cortical PDGFR-b and M-CSF
receptor mRNA expression. Using colocalization we found
that glomerular macrophages had reduced IL-1b and MCP-1
protein expression. Late imatinib treatment significantly
reduced proteinuria, serum blood urea nitrogen, and
creatinine, and reversed renal histopathological changes. We
show that imatinib has renoprotective and therapeutic
properties and provide pre-clinical work that will need to be
confirmed in patients with crescentic glomerulonephritis.
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Crescentic glomerulonephritis (GN) is characterized clini-
cally by the rapid deterioration of renal function and
histologically by mononuclear cell infiltration in the
glomeruli and tubulointerstitium, glomerular cell prolifera-
tion, necrotizing glomerular lesions, crescent formation, and
eventual glomerulosclerosis. In Wistar-Kyoto (WKY) rats, a
small dose of rabbit anti-rat glomerular basement membrane
(GBM) antiserum (nephrotoxic serum, NTS) induces severe
proliferative and necrotizing GN, with crescent formation
resembling human crescentic GN. It has been considered that
the cardinal pathological features of crescentic GN are
mediated largely by the infiltration of monocytes/macro-
phages and T cells.1,2 In addition, several studies have
suggested that some types of growth factors, such as platelet-
derived growth factor (PDGF), transforming growth factor-b,
and connective tissue growth factor, may, at least in part,
contribute to the process of glomerular crescent formation.3–5
Imatinib (Gleevec, Novartis Pharmaceuticals Co., Basel,
Switzerland), a selective tyrosine kinase inhibitor that inhibits
c-Abl, c-Kit, and PDGF receptors (PDGFRs), has been shown
to be highly active in patients with Philadelphia chromo-
some-positive chronic myeloid leukemia and acute lympho-
blastic leukemia, as well as in gastrointestinal stromal
tumors.6 The therapeutic benefit of imatinib in animal
models of kidney diseases, such as mesangial proliferative
glomerulonephritis,7 chronic allograft nephropathy,8 diabetic
nephropathy,9 lupus nephritis,10,11 and unilateral obstructive
nephropathy,12 has been reported. In total, these studies have
shown that the beneficial effects of imatinib therapy are the
result of its inhibitory action on PDGF, leading to a reduction
of glomerular cell proliferation and extracellular matrix
accumulation.
Recently, imatinib has been shown to have potential
immunomodulatory effects on various cell types, includ-
ing monocytes/macrophages and T cells. Treatment with
imatinib significantly inhibited glomerular macrophage
infiltration in mouse models of diabetic nephropathy9 and
lupus nephritis.10 Although the precise mechanism of the
macrophage inhibition by imatinib remains obscure, there
is evidence that imatinib has an inhibitory effect on
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macrophage colony-stimulating factor (M-CSF)/c-fms sig-
naling in macrophage development.13,14 M-CSF, acting
through its receptor c-fms, is the major macrophage growth
factor, and it has been shown to play a key role in
macrophage accumulation during renal tissue injury.15
Recently, Paniagua et al.14 reported that imatinib significantly
inhibited c-fms and the activity of its downstream signaling
molecule, Akt, in macrophage culture. On the other hand,
imatinib also has inhibitory effects on T-cell proliferation
and response. When stimulated through the T cell receptor
and CD28, by mitogens or by antigens imatinib reduced the
expansion of CD4þ and CD8þ T cells.16–18 Sinai et al.19
recently showed that imatinib induced the apoptosis of
naive and memory CD8þ T cells in vitro and diminished
memory CD8þ T cells’ response to Listeria monocytogenes
infection in vivo.
In this study, we showed that in vivo treatment with
imatinib had preventive and therapeutic effects on rat anti-
GBM glomerulonephritis induced by NTS in WKY rats by
reducing glomerular macrophage influx and associated
cytokine production in glomeruli, but not by reducing
glomerular CD8þ cells.
RESULTS
Imatinib treatment reduces proteinuria in rats with NTS-N
The experimental design is described in Figure 1. The rats
treated with vehicle developed proteinuria starting on day 4.
In the early treatment study, urinary protein excretion in rats
treated with imatinib was significantly decreased compared
with that in controls at each time point (day 4, Po0.01; day
7, Po0.05; and day 13, Po0.001) (Figure 2a). In the late
treatment study, urinary protein excretion of control rats
reached 143.55±15.17 mg/day on day 20, which was
significantly higher than that on day 7 (Po0.01) (Figure 2b).
Late imatinib treatment, which was performed from days
7 to 20, also significantly reduced the urinary protein level on
day 20 (Po0.01) (Figure 2b).
Imatinib treatment preserves and reverses renal function in
rats with NTS-N
Vehicle-treated rats with NTS nephritis (NTS-N) (WKY-
Vehicle) had high serum blood urea nitrogen (BUN) and
creatinine levels starting on day 4. In the early treatment
study, treatment with imatinib significantly reduced serum
BUN and creatinine levels in imatinib-treated rats compared
with those similarly treated in control rats on days 4, 7, and
13 (BUN: Po0.05, Po0.001, and Po0.05; creatinine:
Po0.05, Po0.0001, and Po0.001, respectively, Table 1). In
the late treatment study, the serum BUN and creatinine levels
of control rats with NTS-N (WKY-Vehicle) were 29.40±0.96
and 0.34±0.02 mg/100 ml, respectively, on day 20 (Table 1).
On the other hand, the serum BUN and creatinine levels
on day 20 were significantly lower in imatinib-treated rats
than those in the control group (WKY-Vehicle) (BUN:
25.86±1.57 mg/100 ml, Po0.05; creatinine: 0.25±0.01 mg
per 100 ml, Po0.001; Table 1).
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Figure 1 | Experimental design. A total of 95 female WKY rats
were injected intravenously with 20 ml of NTS on day 0. Groups of
animals were given either imatinib (50 mg/kg) or vehicle daily by
an intraperitoneal injection from day 1 to day 4, 7, or 13 in the
early treatment study, and from days 7 to 20 in the late treatment
study; the rats were then killed. Vehicle-treated groups received
an equal volume of sterile water.
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Figure 2 | Imatinib treatment reduces proteinuria in rats with
NTS-N. Urinary protein levels in the (a) early treatment study and
(b) late treatment study of vehicle-treated and imatinib-treated
rats with NTS-N on the day indicated. The horizontal dotted lines
show the level of proteinuria in normal WKY rats. Data are
expressed as mean±s.e.m. The Mann–Whitney test: *Po0.05,
**Po0.01, and ***Po0.001 vs NTS-N rats with the same duration
of vehicle treatment. NS, not significant.
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Imatinib reduces the percentage and the absolute number of
peripheral CD8þ cells but not CD3þ and CD4þ cells in rats
with NTS-N
The effect of imatinib on the circulating T-cell subsets was
analyzed in the acute phase of NTS-N (days 4 and 7). When
compared with vehicle treatment on day 7, imatinib
treatment reduced significantly both the percentage and the
absolute number of peripheral CD8þ cells (percentage:
27.92±1.00 vs 22.49±1.00%, Po0.01; absolute number:
6.91±0.86 102/ml vs 3.55±0.57 102/ml, Po0.01, vehicle-
treated vs imatinib-treated rats, respectively) but not CD3þ
and CD4þ cells (data not shown). Thus, there was a
significant increase in the CD4þ /CD8þ cell ratios
(1.48±0.08 vs 1.97±0.15, Po0.01). However, there was no
significant difference in the CD8þ cell percentage
(24.65%±1.76% vs 26.04%±1.70%, NS, not significant)
and number (8.22±1.31 vs 6.77±0.98 102/ml, NS) between
vehicle- and imatinib-treated rats on day 4.
Early and late treatment with imatinib reduces fibrin
deposition in rats with NTS-N
Prominent glomerular fibrin deposition was observed
in control rats starting on day 4, with a peak on day 7
(Figure 3a). The semiquantitative evaluation of fibrin
deposition showed a significantly reduced fibrin score in
imatinib-treated rats compared with that in control rats at
each time point (Figure 3e). Rabbit immunoglobulin G (IgG)
was detected in an intense linear pattern along the glomerular
capillaries in vehicle- and imatinib-treated rats with NTS-N
(Figure 3c and d). Rat IgG was also detected along the
glomerular capillaries on days 7, 13, and 20. Rat C3 staining
was faint at each time point. There was no significant
difference in rabbit IgG, rat IgG, and rat C3 glomerular
staining between vehicle- and imatinib-treated rats with
NTS-N (data not shown). Furthermore, there was no
significant difference in the levels of serum anti-rabbit IgG
antibody between vehicle- and imatinib-treated rats with
NTS-N at each time point (OD value, day 4: 0.37±0.03 vs
0.36±0.04, NS; day 7: 0.39±0.03 vs 0.39±0.03, NS; day 13:
0.31±0.05 vs 0.30±0.03, NS; and day 20: 0.76±0.13 vs
0.90±0.15, NS, vehicle-treated rats with NTS-N vs imatinib-
treated rats with NTS-N; Normal WKY rats: 0.20±0.002).
These findings suggest that imatinib treatment does not
significantly affect the process of heterologous antibody
deposition or autologous antibody production.
Table 1 | Effects of imatinib on renal function by the study
group
Group BUN (mg/100 ml) Cr (mg/100 ml)
WKY-NTS() (N=6) 22.75±1.02 0.20±0.00
Early treatmenta
WKY-Vehicle
Day 4 (N=12) 32.48±1.63 0.29±0.02
Day 7 (N=13) 31.68±0.85 0.34±0.01
Day 13 (N=12) 32.00±1.75 0.33±0.01
WKY-Imatinib
Day 4 (N=10) 20.89±1.91** 0.24±0.01*
Day 7 (N=10) 22.84±1.38** 0.23±0.01#
Day 13 (N=12) 25.43±0.89* 0.24±0.01***
Late treatmentb
WKY-Vehicle
Day 20 (N=13) 29.4±0.96 0.34±0.02
WKY-Imatinib
Day 20 (N=13) 25.86±1.57* 0.25±0.01***
BUN, blood urea nitrogen; Cr, creatinine; WKY, Wistar-Kyoto rats.
Data are mean±s.e.m.
Mann–Whitney test: *Po 0.05, **Po 0.01, ***Po 0.001, #Po 0.0001 vs NTS-N rats
with the same duration of vehicle treatment.
aThe rats were treated with either vehicle or imatinib from day 1 to day 4, 7, or 13.
bThe rats were treated with either vehicle or imatinib from day 7 to 20.
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Figure 3 | Representative fibrin and rabbit IgG staining by
immunofluorescence microscopy. Immunofluorescent staining
for (a, b) fibrin and (c, d) rabbit IgG in (a, c) vehicle-treated NTS-N
and (b, d) imatinib-treated NTS-N rats on day 7. (e)
Semiquantitative assessment of fibrin deposition in each group.
Each group contained 10–13 rats, and 50 glomeruli per rat were
evaluated in a blind manner. Data are expressed as mean±s.e.m.
The Mann–Whitney test: *Po0.01 and **Po0.001 vs vehicle-
treated NTS-N rats.
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Early and late treatment with imatinib ameliorates NTS-N
In control rats with NTS-N, the glomeruli on days 4 and 7
exhibited endocapillary proliferation, severe fibrinoid necro-
sis, and cellular crescent formation. Figure 4a and b shows
typical silver-stained sections of glomeruli on days 4 and 7,
respectively, in this group of rats. The crescentic glomeruli
started to transform from cellular to fibrocellular on day 13,
and there was a mixture of fibrocellular and fibrous crescents
on day 20 (Figure 4c). Consistent with the urinary protein
and serum creatinine data, crescent formation and fibrinoid
necrosis were markedly reduced in imatinib-treated NTS-N
rats (Figure 4d–f). The morphological analysis of renal tissue
damage revealed that glomerular injury was ameliorated by
early imatinib treatment, as well as by late imatinib
treatment. Imatinib-treated NTS-N rats developed fewer
crescents and less necrosis, and had a lower crescent score
than did control rats at each time point (Figure 4g–i).
Early and late treatment with imatinib reduces macrophage
accumulation but not CD8þ cell influx in NTS-N
To identify the cell phenotype of leukocytes affected by
imatinib treatment, ED1þ and CD8þ cells in glomeruli
were examined. Immunostaining for ED1 in control NTS-N
rats showed intense glomerular staining, whereas significantly
less staining was observed in imatinib-treated NTS-N rats at
each time point (Figure 5a–d and g). The CD8þ cell
numbers per glomerular cross-section in imatinib-treated
NTS-N rats on days 4 and 7 were identical to those in vehicle-
treated NTS-N rats (Figure 5e, f, and h).
Early and late treatment with imatinib reduces pro-inflam-
matory cytokine expression in NTS-N
As pro-inflammatory cytokines are fundamental in the
pathogenesis of NTS-N, they were examined by immuno-
histochemistry. Immunostaining for interleukin (IL)-1b and
monocyte chemoattractant protein 1 (MCP-1) showed a
strong expression in the glomeruli of control rats. In contrast,
significantly decreased glomerular staining was observed in
imatinib-treated rats (Table 2, Figure 6a–d). Double im-
munostaining of ED1 with either IL-1b or MCP-1 was
performed to confirm that a significant reduction of these
molecules in glomeruli is associated with the inhibition of
macrophage accumulation by imatinib treatment. A large
number of ED1þ macrophages exhibited double staining for
either IL-1b or MCP-1 in control rats with NTS-N (Figure 7a
and c). In imatinib-treated rats, there was a potent reduction
of glomerular macrophage accumulation, along with an
inhibition of IL-1b or MCP-1 expression that was colocalized
with glomerular macrophages (Figure 7b and d).
Early and late treatment with imatinib reduces PDGFR-b and
c-fms expressions in NTS-N
To determine the importance of PDGFR signaling as a target
of imatinib, the expressions of PDGFR-b and c-fms, which is
known as a family of protein tyrosine kinase receptors, and
their ligands PDGF-B and M-CSF, were studied. Imatinib
treatment attenuated the PDGFR-b mRNA upregulation at
each time point. On the other hand, a significant difference in
the PDGF-B mRNA expression was seen only on day 13
(Po0.01). M-CSF is a fundamental chemokine for macro-
phage accumulation and local proliferation in NTS-N.20 The
ability of imatinib to inhibit M-CSF receptor c-fms activity is
generally accepted.13 In this study, imatinib treatment
significantly attenuated the c-fms mRNA expression on day
7 (Po0.001), day 13 (Po0.05), and day 20 (Po0.01),
whereas a significant difference in the M-CSF mRNA
expression was found only on day 13 (Po0.01) (Figure 8a–d).
DISCUSSION
In this study, early and late imatinib treatment decreased
urinary protein excretion, serum BUN and creatinine levels,
glomerular crescent formation, and the necrotizing glomer-
ular lesions, along with a dramatic reduction of glomerular
macrophage accumulation and macrophage-associated
pro-inflammatory cytokine protein expressions, in an
experimental model of crescentic GN.
Our study’s most substantial finding was that the
administration of imatinib potently reduced glomerular
macrophage influx, which in turn suppressed the protein
expression of macrophage-associated cytokines, MCP-1 and
IL-1b, in the glomeruli. The double staining of ED1 and these
cytokines indicated that glomerular staining of these
cytokines was macrophage-dependent and hence, the double
staining was abolished, along with macrophage reduction,
after imatinib treatment in NTS-N rats. Imatinib has been
shown to reduce glomerular macrophage accumulation in
animal models of kidney diseases, such as diabetic nephro-
pathy9 and lupus nephritis.10 However, little evidence is
available regarding the potential mechanisms of macrophage
reduction by imatinib treatment in these animal models.
Contrary to these reports, we found recently that imatinib
treatment resulted in an increased accumulation of macro-
phages in the glomeruli in cryoglobulinemic membranopro-
liferative glomerulonephritis (MPGN).21 This finding is
consistent with the result of a study of imatinib treatment
in the rat anti-Thy 1.1 model of GN.22 Thus, the effect of
imatinib on macrophages is pleiotrophic among experimen-
tal models of renal diseases. The explanation for this
pleiotrophic effect awaits further studies.
In addition to suppressing pro-inflammatory cytokines,
IL-1b, and MCP-1, imatinib inhibits PDGFR-b and c-fms
expressions. Although several reports have suggested the
upregulation of PDGFRs in human crescentic glomerulone-
phritis, little evidence is available about the profile of
PDGFRs in this model. We found increased PDGFR-b and
PDGF-B mRNA levels already on day 4 in NTS-N rats
compared with normal WKY rats, and they remained
upregulated thereafter, indicating that PDGF signaling path-
way may be contributing to the pathogenesis of this model of
glomerulonephritis. This increased PDGFR-b mRNA level
was significantly reduced by imatinib treatment. Therefore, it
is tempting to speculate that imatinib may prevent renal
Kidney International (2009) 75, 1060–1070 1063
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damage at least in part through PDGF signaling blockade,
consistent with other experimental models of glomerulone-
phritis. However, the manner by which the decrease of the
PDGFR-b mRNA expression contributed to macrophage
influx reduction, an essential feature of this study, remains
unclear. On the other hand, this study provided in vivo
evidence that imatinib treatment reduced renal cortical
M-CSF receptor c-fms mRNA expression that was
significantly upregulated compared with normal controls
(WKY-NTS(-)) rats. M-CSF is a fundamental chemokine for
macrophage accumulation and local proliferation in animal
models of NTS-N and unilateral ureteral obstruction,20 and
its receptor c-fms belongs to the same family of protein
tyrosine kinase receptors as PDGFR-a and PDGFR-b.23,24
Thus, imatinib has the potential to inhibit the c-fms signaling
pathway. Recently, Dewar et al.13 showed that imatinib also
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Figure 4 | Representative renal histology and quantification of crescent formation and necrotizing glomerular lesions. Renal
histology on (a, d) day 4, (b, e) day 7, and (c, f) day 20 in (a–c) vehicle-treated and (d–f) imatinib-treated rats with NTS-N. Original
magnification, 400 (a, d), 200 (b, e), and 100 (c, f). (g–i) Semiquantitative assessment of the crescent score and quantitative
assessment of crescent formation and fibrinoid necrosis in each group. Each group contained 10–13 rats, and 100 glomeruli per rat were
evaluated in a blind manner. Data are expressed as mean±s.e.m. The Mann–Whitney test: *Po0.01, **Po0.001, and ***Po0.0001 vs
vehicle-treated NTS-N rats.
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specifically targets c-fms at therapeutic concentrations.
Moreover, they found that the abrogation of c-fms tyrosine
phosphorylation by imatinib was a direct mechanism for the
inhibitory effect of imatinib on monocyte and/or macro-
phage growth and function in vitro.25,26 These lines of
evidence suggest that M-CSF/c-fms signaling inactivation
may have been one of the fundamental factors in the
mechanism of macrophage reduction by imatinib treatment
in this study. The fact that imatinib did not reduce the c-fms
mRNA expression on day 4 indicates that not only c-fms
reduction but also multiple factors, such as chemokines,
adhesion molecules, and co-stimulatory factors, play a part in
glomerular macrophage reduction, especially in the early
phase of this experimental model of GN.
Another important finding of this study is that imatinib
treatment had a therapeutic effect in NTS-N even when it was
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Figure 5 | Representative photomicrograph and quantification of macrophage infiltration in vehicle-treated and imatinib-treated
rats with NTS-N. Immunostaining for (a–d) ED1 and (e, f) CD8 in (a, c, e) vehicle-treated and (b, d, f) imatinib-treated rats with NTS-N on day 7.
(g) Semiquantitative assessment of the ED1 score and (h) quantitative assessment of CD8þ cells per glomerular cross-section in each group. Each
group contained 10–13 rats, and 50 glomeruli per rat were evaluated in a blind manner. Data are expressed as mean±s.e.m. The Mann–Whitney
test: *Po0.01 and **Po0.001 vs vehicle-treated NTS-N rats.
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administered after crescent formation and necrotizing lesions
had been fully established. Late treatment with imatinib
significantly accelerated glomerular injury repair and
reversed renal dysfunction based on proteinuria and the
serum BUN and creatinine levels. This suggests that imatinib
has potential as a novel therapeutic agent for human
crescentic glomerulonephritis. However, the molecular
mechanism of the therapeutic effect remains obscure. The
first possible mechanism is the reduction of macrophages and
macrophage-associated cytokines, similar to the preventive
effects of imatinib. In fact, glomerular macrophage accumu-
lation was also attenuated, and the expressions of IL-1b and
MCP-1 in glomeruli that were colocalized with macrophages
were significantly suppressed by late treatment with imatinib.
An interaction between macrophage accumulation and renal
fibrosis in NTS-N has been suggested in earlier reports using
an anti-MCP-1 antibody.27,28 The second possible mechan-
ism of action is PDGFR inhibition. Recently, we attenuated
the established cryoglobulinemic MPGN in Thymic Stromal
lymphopoietin (TSLP) transgenic mice using a PDGFR-b-
specific inhibitor, APB5.29 APB5 treatment significantly
attenuated established extracellular matrix accumulation,
but did not affect immunological factors, such as circulating
cryoglobulins, serum Ig levels, or glomerular complement
deposition. This result strongly suggests that the PDGFR-b
inhibition is involved in the therapeutic effects of imatinib.
In experimental crescentic glomerulonephritis, the deple-
tion of circulating CD8þ cells and the subsequent reduction
of glomerular CD8þ cells with an anti-CD8 monoclonal
antibody (OX8) have been shown to prevent the initiation
and progression of renal injury in both WKY2 and Sprague-
Dawley rats.30,31 In this study, the lymphocyte subpopula-
tions determined by flow cytometry indicated a decrease in
the peripheral CD8þ cell percentage and number, whereas
the peripheral CD3þ and CD4þ cell numbers remained
unchanged after imatinib treatment. The results of this study
are consistent with recent reports that indicate the inhibitory
effect of imatinib on CD8þ T cells in experimental18,19 and
clinical studies.32,33 CD8þ cells appear to be indirectly
involved in glomerular injury by accumulating monocytes/
macrophages through the induction of cytokines and the
upregulation of ICAM-1 in NTS-N.30 Unexpectedly, imatinib
treatment did not reduce glomerular CD8þ cell accumula-
tion in NTS-N, indicating that the renal protective effect of
imatinib in this crescentic nephritis model is independent of
a decrease in circulating CD8þ cell number and percentage.
In conclusion, imatinib treatment showed renal preventive
and therapeutic effects in rats with NTS-N, with a dramatic
reduction of glomerular macrophage infiltration, which is an
indispensable factor in the pathogenesis of this GN in vivo.
These results strongly suggest a promising therapeutic use of
imatinib in patients with necrotizing and crescentic GN, both
during the initiation of injury and after the necrotizing and
crescentic GN has been well established.
MATERIALS AND METHODS
NTS
NTS was prepared as described earlier.34 The activity and specificity
of NTS were tested by indirect immunofluorescence microscopy of
frozen sections of a normal rat kidney.
Experimental protocol
The experimental protocol for this study was reviewed and approved
by the Animal Care Committee of Showa University in Tokyo.
Seven-week-old female WKY rats weighing 150 g were purchased
from Charles River Japan (Atsugi, Kanagawa, Japan) and used in all
the experiments. The animals were housed in the animal care facility
of Showa University (25 1C, 50% humidity, 12-h dark/light cycle)
Table 2 | Results of IL-1b and MCP-1 staining
Group IL-1b score MCP-1 score
Early treatmenta
WKY-Vehicle
Day 4 (N=12) 2.35±0.24 2.32±0.27
Day 7 (N=13) 1.68±0.19 1.16±0.16
Day 13 (N=12) 1.65±0.14 1.05±0.07
WKY-Imatinib
Day 4 (N=10) 1.17±0.12* 1.41±0.21*
Day 7 (N=10) 0.90±0.10* 0.45±0.07*
Day 13 (N=12) 0.79±0.12* 0.46±0.08*
Late treatmentb
WKY-Vehicle
Day 20 (N=13) 1.27±0.15 0.78±0.06
WKY-Imatinib
Day 20 (N=13) 0.57±0.05* 0.32±0.08*
IL-1b, interleukin-1b; MCP-1, monocyte chemoattractant protein 1.
Data are mean±s.e.m.
Mann–Whitney test: *Po 0.01 vs NTS-N rats with the same duration of vehicle
treatment.
aThe rats were treated with either vehicle or imatinib from day 1 to day 4, 7, or 13.
bThe rats were treated with either vehicle or imatinib from day 7 to 20.
ImatinibVehicle
MCP-1
IL-1β
Figure 6 | Representative photomicrograph of
immunostaining for IL-1b and MCP-1 in vehicle-treated and
imatinib-treated rats with NTS-N. Immunostaining for (a, b)
IL-1b and (c, d) MCP-1 in (a, c) vehicle-treated and (b, d) imatinib-
treated rats with NTS-N on day 4.
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with free access to food and water. A total of 95 female WKY rats
were injected intravenously with 20 ml of NTS on day 0. Groups of
animals were given either imatinib (50 mg/kg; Novartis Pharma-
ceuticals, Basel, Switzerland) or vehicle daily by an intraperitoneal
injection, from day 1 to day 4, 7, or 13 in the early treatment
study, and from days 7 to 20 in the late treatment study; the rats
were then killed (Figure 1). Vehicle-treated groups received an equal
volume of sterile water. Six female WKY rats at the age of 7 weeks
were used as normal controls. At the end of the study, the rats were
anesthetized, their blood was collected by cardiac puncture, and
their organs were collected. Renal tissue was divided; some portions
were snap-frozen in liquid nitrogen and some portions were fixed in
2% paraformaldehyde/ phosphate-buffered saline (PBS) for later
use.
Proteinuria and creatinine determination
For analysis of proteinuria, the rats were housed individually in
metabolic cages for the 24-h urine collection. Urine samples were
collected on the day before killing. Urinary protein was determined
using the Biuret method. BUN and creatinine levels were measured
using an automated analyzer (Hitachi, Tokyo, Japan) according to
the manufacturer’s instructions.
Measurement of circulating anti-rabbit IgG antibody
The level of circulating anti-rabbit IgG antibody in rats with NTS-N
was measured by ELISA, according to the ELISA procedure as
described earlier.34 Microtiter plates (Nunc, Roskilde, Denmark)
were coated with 5 mg/ml of purified rabbit IgG (ZYMED
Laboratories, San Francisco, CA, USA). Plates were then incubated
with 1:400 diluted serum samples from nephritic rats. The assay was
developed with an alkaline phosphatase-conjugated rabbit anti-rat
IgG antibody (Sigma Chemical Co., St Louis, MO, USA). The
absorbance at 405 nm was analyzed with microplate reader.
Flow cytometry
Isolated lymphocytes from peripheral blood were labeled with
specific monoclonal antibodies (CD3-PE, CD4-FITC, and CD8-PE;
BD Pharmingen, San Diego, CA, USA). The proportion of cells
positive for these molecules was determined by flow cytometry
(FACScan, BD Pharmingen), and the results were analyzed using
Cell Quest software.
Light microscopic study
Tissues fixed in 2% paraformaldehyde/PBS were embedded in
paraffin using routine protocols. The paraffin-embedded tissues
were sectioned at 4mm for routine staining with hematoxylin and
eosin and periodic-acid Schiff. Two-mm-thick sections were used for
periodic-acid methenamine silver stains (silver). The number of
crescentic or necrotizing glomeruli per 100 glomeruli of each rat was
calculated and expressed as a percentage. The percentage of area
occupied by crescents in each glomeruli was estimated and assigned
one of the following scores: 0, absent; 1, o1/4; 2, between 1/4 and
1/2; 3, between 1/2 and 3/4; and 4, more than 3/4 of the whole
glomerulus.35 The mean score of 50 glomeruli was then calculated as
the crescent score.
Immunohistochemistry
The monoclonal antibodies used in this study were mouse anti-rat
ED1 antibody (BMA, Augst, Switzerland) as a macrophage marker;
mouse anti-rat IL-1b antibody (clone number: SILK 6; Cosmo Bio,
Tokyo, Japan); and mouse anti-rat CD8 antibody (clone number:
X8; Antigenix America, Huntington Station, NY, USA). In addition,
polyclonal antibodies against goat anti-rat MCP-1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and goat anti-rat IL-1b (Santa
Cruz Biotechnology) were also used. Biotinylated rabbit anti-mouse
IgG or anti-goat IgG antibody and peroxidase-conjugated streptavidin
(LSAB 2 Kit/HRP) were purchased from Dako (Glostrup, Denmark).
Immunohistochemical staining for ED1, CD8, IL-1b, and MCP-1
was performed as follows: the paraffin sections of renal tissues were
dewaxed, washed in PBS, drained, and incubated overnight at 4 1C,
with the anti-ED1, CD8, IL-1b, and MCP-1 antibodies as the
primary antibodies. They were then washed thrice in PBS and
incubated with a secondary antibody, the biotinylated rabbit anti-
mouse IgG or the anti-goat IgG antibody. After the endogenous
peroxidase was inactivated by incubation with 0.3% H2O2 in
methanol, the sections were incubated with an LSAB 2 Kit/HRP and
developed using diaminobenzedine (DAKO) as the substrate to
produce a brown stain, and the sections were counterstained with
hematoxylin.
Two-color immunostaining was used to detect the colocalization
of IL-1b/ED1 and MCP-1/ED1. The paraffin sections were dewaxed,
washed in PBS, drained, and incubated overnight at 4 1C, with the
goat anti-IL-1b (1:10 dilution) or MCP-1 (1:15 dilution) antibodies
as the primary antibodies. They were then washed thrice in PBS and
incubated with a secondary antibody, the biotinylated rabbit anti-
goat IgG antibody. After the endogenous peroxidase was inactivated
by incubation with 0.3% H2O2 in methanol, the sections were
incubated with LSAB 2 Kit/HRP and developed using diaminoben-
zedine (DAKO) as the substrate to produce a brown stain. To
denature all antibodies bound to the tissue, the sections were
microwaved twice for 5 min. The sections were then washed in PBS
and incubated with the second mouse monoclonal antibody, ED1
(1:50 dilution). The slides were once again washed in Tris-buffered
saline (TBS) and incubated with the secondary antibody, rabbit
IL-1β
MCP-1
ImatinibVehicle
Figure 7 | Double immunostaining for ED1 with either IL-1b or
MCP-1 in vehicle-treated rats with NTS-N on day 7. Kidney
sections were stained using two-color immunohistochemistry
with ED1 being stained red, and (a, b) IL-1b and (c, d) MCP-1
stained brown in (a, c) vehicle-treated and (b, d) imatinib-treated
rats. A large number of ED1þ macrophages in the glomeruli were
double stained by IL-1b and MCP-1.
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anti-mouse biotinylated (diluted 1:500, DAKO), which was applied
for 30 min at room temperature. The slides were then washed in
TBS, and the third layer, streptavidin alkaline phosphatase (DAKO),
was applied for 45 min at room temperature. The slides were then
washed in TBS, and the red color was developed using a Fuchsin
substrate kit (DAKO). Once a suitable red color had developed, the
slides were washed in water and then coverslipped with an aqueous
mounting medium.
CD8þ cells were estimated by counting the numbers of these
cells within 50 glomeruli and dividing the total number by 50. The
extent of ED1, IL-1b, and MCP-1 staining of each glomerulus was
graded for 50 glomeruli on a 4-point scale: 0, absent; 1, weak; 2,
moderate; and 3, severe.36,37 The mean score was then calculated as
the score of each staining. All the histological analyses were
performed by two investigators without knowledge of the origin
of the slides, and the mean values were calculated.
Immunofluorescence
The tissues were snap-frozen in liquid nitrogen and cut
into 4-mm-thick sections. The deposits of rabbit IgG, rat C3, rat
fibrin, and rat IgG in the kidney sections were evaluated by
staining with fluorescein-isothiocyanate-conjugated goat anti-
rabbit IgG, anti-rat C3, anti-rat fibrinogen (Cappel;
Organon Teknika, Durham, NC, USA) and rabbit anti-rat
IgG (Sigma Chemical Co.) using a method earlier described.33
The extent of fibrin deposition in each glomerulus was graded
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Figure 8 | mRNA expressions for PDGFR-b, PDGF-B, c-fms, and M-CSF in vehicle-treated and imatinib-treated rats with NTS-N as
determined by real-time RT-PCR. Real-time RT-PCR for (a) PDGFR-b, (b) PDGF-B, (c) c-fms, and (d) M-CSF in each group. Each group
contained 10–13 rats. The horizontal dotted lines show the expression levels in normal WKY rats. Data are expressed as mean±s.e.m. The
values were normalized to the GAPDH values and then expressed as relative quantification. The Mann–Whitney test: *Po0.05, **Po0.01,
and ***Po0.001 vs vehicle-treated NTS-N rats.
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for 50 glomeruli using a 4-point scale: 0, absent; 1, o1/3; 2,
between 1/3 and 2/3; and 3, more than 2/3 of the whole
glomerulus. The mean score of 50 glomeruli was then calculated
as the fibrin score.
Real-time RT-PCR
Gene expressions of rat PDGFR-b, PDGF-B, c-fms, M-CSF, and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were ana-
lyzed using real-time reverse transcriptase-PCR (RT-PCR). Briefly,
kidney tissues (cortex) were homogenized using a TissueLyser
(QIAGEN, Hilden, Germany), and total RNA was isolated using an
RNeasy Fibrous Tissue Mini kit (QIAGEN), in accordance with the
manufacturer’s instructions. cDNA synthesis was carried out using
the SuperScript First-Strand Synthesis System for RT-PCR (Invitro-
gen, Carlsbad, CA, USA). Pre-designed TaqMan probe sets for the
targets indicated above were purchased from Applied Biosystems
(Foster City, CA, USA). Each probe has a fluorescent reporter dye
(FAM) linked to its 50-end and a downstream quencher dye
(TAMRA) linked to its 30-end. Each reaction consisted of 25 ml
containing 2 Universal Master Mix (Applied Biosystems),
primers, labeled probes, and cDNA. The amplification conditions
consisted of 40 cycles at 95 1C for 15 s and 60 1C for 1 min after
incubation at 95 1C for 10 min. Amplification and fluorescence
measurements were performed using the MicroAmp Optical 96-
Well Reaction Plate on the ABI PRISM 7700 Sequence Detection
System (Applied Biosystems). mRNA expressions were normalized
using GAPDH as an endogenous control to correct for the
differences in the amount of total RNA added to each reaction.
Statistical analysis
Data were recorded as means±s.e.m. The Mann–Whitney test was
performed, and values of Po0.05 were considered statistically
significant.
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